Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) EPS (Weighted Average and Diluted) (2016 - 2024)

Historic EPS (Weighted Average and Diluted) for Harvard Bioscience (HBIO) over the last 16 years, with Q1 2024 value amounting to -$0.11.

  • Harvard Bioscience's EPS (Weighted Average and Diluted) fell 120000.0% to -$0.11 in Q1 2024 from the same period last year, while for Mar 2024 it was -$0.06, marking a year-over-year increase of 4545.45%. This contributed to the annual value of -$0.12 for FY2019, which is 41767.43% down from last year.
  • Harvard Bioscience's EPS (Weighted Average and Diluted) amounted to -$0.11 in Q1 2024, which was down 120000.0% from -$0.02 recorded in Q2 2023.
  • In the past 5 years, Harvard Bioscience's EPS (Weighted Average and Diluted) ranged from a high of $0.06 in Q2 2022 and a low of -$0.17 during Q1 2022
  • In the last 5 years, Harvard Bioscience's EPS (Weighted Average and Diluted) had a median value of -$0.03 in 2023 and averaged -$0.05.
  • In the last 5 years, Harvard Bioscience's EPS (Weighted Average and Diluted) surged by 70000.0% in 2022 and then crashed by 120000.0% in 2024.
  • Harvard Bioscience's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.04 in 2020, then skyrocketed by 75.0% to -$0.01 in 2021, then soared by 700.0% to $0.06 in 2022, then crashed by 133.33% to -$0.02 in 2023, then tumbled by 450.0% to -$0.11 in 2024.
  • Its EPS (Weighted Average and Diluted) was -$0.11 in Q1 2024, compared to -$0.02 in Q2 2023 and $0.01 in Q1 2023.